Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis 

Ross L. Levine, Martha Wadleigh, Jan Cools, Benjamin L. Ebert, Gerlinde Wernig, Brian J.P. Huntly, Titus J. Boggon, Iwona Wlodarska, Jennifer J. Clark, Sandra Moore, Jennifer Adelsperger, Sumin Koo, Jeffrey C. Lee, Stacey Gabriel, Thomas Mercher, Alan D’Andrea,

Stefan Fröhling, Konstanze Döhner, Peter Marynen, Peter Vandenberghe, Ruben A. Mesa, Ayalew Tefferi, James D. Griffin, Michael J. Eck, William R. Sellers, Matthew Meyerson, Todd R. Golub, Stephanie J. Lee, D. Gary Gilliland 

Cancer Cell Volume 7, Issue 4, Pages 387-397 (April 2005)

DOI: 10.1016/j.ccr.2005.03.023

Copyright © 2005 Elsevier Inc. Terms and Conditions

Figure 1

Cancer Cell 2005 7, 387-397DOI: (10.1016/j.ccr.2005.03.023) Copyright © 2005 Elsevier Inc. Terms and Conditions

Figure 2

Cancer Cell 2005 7, 387-397DOI: (10.1016/j.ccr.2005.03.023) Copyright © 2005 Elsevier Inc. Terms and Conditions

Figure 3

Cancer Cell 2005 7, 387-397DOI: (10.1016/j.ccr.2005.03.023) Copyright © 2005 Elsevier Inc. Terms and Conditions

Figure 4

Cancer Cell 2005 7, 387-397DOI: (10.1016/j.ccr.2005.03.023) Copyright © 2005 Elsevier Inc. Terms and Conditions